Hims & Hers $HIMS Earnings: Subscriber Growth Slows to 9-13%

$HIMS reports Monday after the close, and the vibe on social is equal parts hopeful and nervous. Bloomberg's Week Ahead coverage lays it out cold: subscriber growth has slowed from a very impressive 35% over 16 quarters down to a range of just 9-13% in recent periods. That's not a blip. That's a trend.

The bull case is real, though. Hims and Hers dropped a new AI-native, doctor-led care app just ahead of earnings, which management is pitching as a subscriber retention tool. If it moves the needle on churn, the stock could catch a bid. The platform's direct-to-consumer model still has a defensible moat in telehealth, and the brand has genuine cultural cachet that most healthcare companies would kill for.

The bear case is messier. The FTC has filed a lawsuit alleging misleading subscription practices and privacy violations. That's not a parking ticket. Legal overhangs like this drag on multiples and spook institutional money, which is exactly what a growth-dependent name like $HIMS does not need while it's trying to reaccelerate. The stock is already down roughly 9% this quarter heading into the print.

Retail sentiment on X and YouTube has been split. Bulls are leaning on the AI product launch as a potential re-rating catalyst, essentially betting that the company can pivot from a weight-loss-hype trade into a durable digital health platform. Bears are pointing to the deceleration math and asking whether the AI app is a genuine growth lever or just a well-timed press release.

• Subscriber growth: dropped from 35% to 9-13%
• New AI care app launched pre-earnings
• FTC lawsuit: misleading subscriptions and privacy violations
• Stock performance: down about 9% this quarter

The market's backdrop does not exactly help either. Geopolitical noise from the Iran-Hormuz situation is keeping broader risk appetite cautious, and the weak July jobs report has investors second-guessing consumer discretionary spending. Telehealth straddles the line between healthcare necessity and consumer luxury, which means macro uncertainty hits HIMS harder than it hits, say, a hospital chain.

Monday after the bell, we find out if an AI doctor's note is enough to write a new chapter for this stock.